 |
Idenix Pharmaceuticals to Present at Three Upcoming Healthcare Conferences
May 8, 2013
|
16.6 KB |
|
| |
CAMBRIDGE, Mass., May 8, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), announced today that Idenix management will present a corporate overview at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15, 2013 at 11:20 a.m. PT at the Encore at the Wynn in Las Vegas, NV; and at the UBS Global Healthca...
|
|
Idenix Pharmaceuticals Reports First Quarter 2013 Financial Results
Apr 30, 2013
|
28.4 KB |
|
| |
CAMBRIDGE, Mass., April 30, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the first quarter ended March 31, 2013.
First Quarter 2013 Financial Results
...
|
|
Idenix Reports Favorable Resistance Profile for IDX719, a Potent, Pan-Genotypic HCV NS5A Inhibitor, at EASL Meeting
Apr 24, 2013
|
25.0 KB |
|
| |
CAMBRIDGE, Mass., April 24, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported detailed resistance data from in vitro studies and from a three-day monotherapy clinical trial of IDX719, the Company...
|
|
Idenix Announces Data Presentation at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL)
Apr 8, 2013
|
11.3 KB |
|
| |
CAMBRIDGE, Mass., April 8, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it will present data on IDX719, the Company's pan-genotypic HCV NS5A inhibitor, at the 48th Annual Meeting of th...
|
|
Idenix Pharmaceuticals Announces Decision by the United States Patent and Trademark Office Patent Trial and Appeal Board in the First Phase of the Interference
Mar 22, 2013
|
12.4 KB |
|
| |
CAMBRIDGE, Mass., March 22, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that the United States Patent and Trademark Office Patent Trial and Appeal Board (USPTO) issued a decision in the fi...
|
|
Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Feb 26, 2013
|
9.1 KB |
|
| |
CAMBRIDGE, Mass., Feb. 26, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc., (Nasdaq:IDIX) announced today that Idenix management will present a corporate overview at the Cowen and Company 33rd Annual Health Care Conference on March 4, 2013 at 2:50 p.m. ET at the Boston Marriott Copley Place and at the Barclays Global Healthcare Conference on ...
|
|
Idenix Pharmaceuticals Reports Fourth Quarter and Year Ended 2012 Financial Results
Feb 25, 2013
|
21.5 KB |
|
| |
CAMBRIDGE, Mass., Feb. 25, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the fourth quarter and year ended December 31, 2012.
HCV Pipeline and Business...
|
|
Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Feb 5, 2013
|
9.1 KB |
|
| |
CAMBRIDGE, Mass., Feb. 5, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc., (Nasdaq:IDIX) announced today that Idenix management will present a corporate overview at the 15th Annual BIO CEO & Investor Conference on February 12, 2013 at 3:00 p.m. ET at the Waldorf Astoria, New York City and at the Leerink Swann 2013 Global Healthcare Conference...
|
|
Idenix Pharmaceuticals Provides Update on IDX184 and IDX19368 Development Programs
Feb 4, 2013
|
57.4 KB |
|
| |
CAMBRIDGE, Mass., Feb. 4, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the Company has elected not to continue its clinical development program for IDX184, a nucleotide polymerase inhibitor...
|
|
Idenix Pharmaceuticals Announces Collaboration With Janssen to Initiate Phase II All-Oral Combination Studies Including IDX719, Simeprevir (TMC435) and TMC647055 for the Treatment of Hepatitis C Virus (HCV)
Jan 28, 2013
|
14.2 KB |
|
| |
CAMBRIDGE, Mass., Jan. 28, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced a non-exclusive collaboration with Janssen Pharmaceuticals, Inc. for the clinical development of all-oral direct-acti...
|
|
Idenix Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference
Jan 2, 2013
|
9.0 KB |
|
| |
CAMBRIDGE, Mass., Jan. 2, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX) announced today that Idenix management will present a corporate overview at the 31st Annual J.P. Morgan Healthcare Conference on January 9, 2013 at 2:00 p.m. PT at the Westin St. Francis in San Francisco.
The live and archived webcast of the comp...
|
|
Idenix Pharmaceuticals to Present at the Oppenheimer 23rd Annual Healthcare Conference
Dec 5, 2012
|
9.0 KB |
|
| |
CAMBRIDGE, Mass., Dec. 5, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX) announced today that Idenix management will present a corporate overview at the Oppenheimer 23rd Annual Healthcare Conference on Wednesday, December 12th, 2012 at 2:45 p.m. ET at the Waldorf Astoria, New York City.
The live and archived webcast of ...
|
|
Idenix Pharmaceuticals to Present at the 2012 Deutsche Bank Access BioFEST Conference
Nov 26, 2012
|
9.1 KB |
|
| |
CAMBRIDGE, Mass., Nov. 26, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX) announced today that Idenix management will present in a fireside chat at the 2012 Deutsche Bank Access BioFEST Conference on December 3, 2012 at 4:00 p.m. ET at the Four Seasons Hotel in Boston.
The live and archived webcast of the company presen...
|
|
Idenix Pharmaceuticals Reports Clinical Data for HCV Drug Candidates - IDX719 and IDX184 - at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
Nov 10, 2012
|
16.4 KB |
|
| |
CAMBRIDGE, Mass., Nov. 10, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the presentation of safety and antiviral activity results for the Company's clinical-stage hepatitis C virus (HCV) dr...
|
|
Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2012 Financial Results and HCV Program Update
Nov 1, 2012
|
23.8 KB |
|
| |
CAMBRIDGE, Mass., Nov. 1, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the third quarter and nine months ended September 30, 2012 and provided an update of it...
|
|
Idenix to Host Conference Call Discussing Third Quarter and Nine Month 2012 Financial Results and HCV Program Update
Oct 25, 2012
|
9.4 KB |
|
| |
CAMBRIDGE, Mass., Oct. 25, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc., (Nasdaq:IDIX) announced today that it will report its financial results for the third quarter of 2012 on Thursday, November 1, 2012 after the U.S. financial markets close.
Idenix management will host a conference call at 4:30 p.m. ET on Thursday, November 1, 2...
|
|
Idenix Pharmaceuticals to Present at the UBS Global Life Sciences Conference
Sep 13, 2012
|
9.0 KB |
|
| |
CAMBRIDGE, Mass., Sept. 13, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX) announced today that Idenix management will present a corporate overview at the UBS Global Life Sciences Conference on Thursday, September 20, 2012 at 11:00 a.m. ET at the Grand Hyatt, New York City.
The live and archived webcast of the company p...
|
|
Idenix Pharmaceuticals to Present at Three Upcoming Investor Conferences
Aug 29, 2012
|
9.4 KB |
|
| |
CAMBRIDGE, Mass., Aug. 29, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), announced today that Idenix management will participate in a panel discussion at Citigroup's 7th Annual Biotech Day on September 5, 2012 at 10:45 a.m. ET at the Mandarin Oriental, Boston, and present corporate overviews at the Stifel Nicolaus Healthcare ...
|
|
Idenix Provides Update on IDX19368 Development Program
Aug 27, 2012
|
13.8 KB |
|
| |
CAMBRIDGE, Mass., Aug. 27, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that the Company received verbal notice from the U.S. Food and Drug Administration (FDA) that a clinical hold has bee...
|
|
Idenix Provides Update on IDX184 Clinical Development Program
Aug 16, 2012
|
13.9 KB |
|
| |
IDX184 has been placed on partial clinical hold by FDA
Management to host a conference call webcast today at 8:30 am ET
CAMBRIDGE, Mass., Aug. 16, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral disease...
|
|
|
shareholder briefcase
investor kit
email alerts
download library
news feeds
Email Page
Print Page
Share this page
Delicious
Digg
Facebook
LinkedIn
Twitter